Log in

Start Your Membership Now

The U.S. Food and Drug Administration (FDA) granted De Novo clearance for Click Therapeutics' CT-132 prescription digital therapeutic (PDT) for the preventive treatment of episodic migraine. The CT-132 PDT is a smartphone app designed to reduce brain hypersensitivity by modulating an individual’s responses to environmental and internal stimuli. The app is intended to be used alongside standard drug therapies,

In a randomized, sham-controlled trial of Click’s PDT showed it could significantly reduce an adult’s number of episodic migraine days per month. A separate clinical study demonstrated that CT-132 performed similarly in individuals . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
Log In
If you are already a member, log in to your account to access this resource and more.

Become A Free Member
You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Tech Updates

Categories
All Bulletins
Submit a Bulletin
  • This field is for validation purposes and should be left unchanged.
  • Max. file size: 98 MB.